Although it didn't disclose data for the study, the Beijing-based biotech company said it planned to seek Chinese approval for tislelizumab in first-line, non-squamous non-small-cell lung cancer. The drug is in several Phase III trials, including in the U.S.
Celgene had been expected to hand the PD-1 checkpoint inhibitor tislelizumab back over to the Chinese company due to its $74 billion acquisition by Bristol-Myers Squibb, which already has its own well-established PD-1 inhibitor, Opdivo.
Discover the top AI-powered EAP providers for 2026. Compare platforms like Kyan Health and Spring Health on triage speed, global reach, and clinical quality to transform workforce wellbeing.